Document is current

Any future updates will be listed below

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review

Crossref DOI link: https://doi.org/10.1684/ejd.2018.3444

Published Online: 2019-05-06

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark